Vicore Announces the Nomination Committee for the 2027 Annual General Meeting

Vicore Pharma Holding (VCRE) announced the composition of its Nomination Committee for the annual general meeting on May 5, 2027.

Rhea-AI Summary

Vicore Pharma Holding (VCRE) announced the composition of its Nomination Committee for the annual general meeting on May 5, 2027.

The three largest shareholders as of August 31, 2026, each appointed a member: Staffan Lindstrand for HealthCap VII, Jan Särlvik for the Fourth Swedish National Pension Fund, and Ivo Staijen for HBM Healthcare Investments (Cayman). Vicore chairman Hans Schikan also serves on the committee and acts as convener.

The committee will propose board membership and compensation, the meeting chairman, auditor and auditor fees, and rules for appointing the 2028 nomination committee. Its proposals will appear in the meeting notice and on Vicore's website.

Key Terms

angiotensin II type 2 receptor agonists, orphan drug, fast track, phase 2b, +1 more

5 terms

angiotensin II type 2 receptor agonists medical

"a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists"

A class of experimental or approved drugs that bind to and activate the angiotensin II type 2 receptor (AT2), a specific protein on cell surfaces involved in regulating blood vessel tone, inflammation, and tissue repair; think of the receptor as a lock and these drugs as keys that turn it on. They matter to investors because successful AT2 agonists can lead to new treatments for cardiovascular, fibrotic, or inflammatory conditions, affecting clinical trial progress, regulatory outcomes, and potential market value.

orphan drug regulatory

"received Orphan Drug and Fast Track designations"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track regulatory

"received Orphan Drug and Fast Track designations"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

phase 2b medical

"the global 52-week Phase 2b ASPIRE trial in IPF"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

idiopathic pulmonary fibrosis medical

"including idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / November 3, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM). The three largest shareholders as of August 31, 2026, have each appointed a member to the Committee.

The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Jan Särlvik, appointed by the Fourth Swedish National Pension Fund, and Ivo Staijen, appointed by HBM Healthcare Investments (Cayman) Ltd. Vicore's chairman, Hans Schikan, is also a member and acts as the convener of the Committee.

The task of the Nomination Committee is to prepare and present proposals for the number of board members to be elected at the AGM, the election of a chairman and other members of the board, board fees, remuneration for committee work, election of a chairman of the AGM, election of auditor, auditor's fees, and proposals for rules for the appointment of the Nomination Committee for the 2028 AGM.

The AGM will take place on May 5, 2027. Shareholders who wish to submit their comments or proposals to the Nomination Committee may do so no later than January 15, 2027, by email to info@vicorepharma.com, or by letter to Vicore Pharma Holding AB, Kornhamnstorg 53, 111 27 Stockholm. The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website.

For further information, please contact:
Hans Jeppsson, CFO, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Announces the Nomination Committee for the 2027 Annual General Meeting

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can Vicore shareholders submit proposals to the nomination committee for the 2027 AGM?

Shareholders may submit comments or proposals by January 15, 2027, by email to info@vicorepharma.com or by letter to Vicore Pharma Holding, Kornhamnstorg 53, 111 27 Stockholm.